| 000 | 01625 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516030631.0 | ||
| 264 | 0 | _c20110527 | |
| 008 | 201105s 0 0 eng d | ||
| 022 | _a1872-7980 | ||
| 024 | 7 |
_a10.1016/j.canlet.2011.02.030 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKachnic, Lisa A | |
| 245 | 0 | 0 |
_aFANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. _h[electronic resource] |
| 260 |
_bCancer letters _cJun 2011 |
||
| 300 |
_a86-93 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 |
_aDNA Breaks, Double-Stranded _xdrug effects |
| 650 | 0 | 4 |
_aDNA Repair _xdrug effects |
| 650 | 0 | 4 |
_aDNA Topoisomerases, Type II _xmetabolism |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xphysiology |
| 650 | 0 | 4 |
_aEtoposide _xpharmacology |
| 650 | 0 | 4 |
_aFanconi Anemia Complementation Group A Protein _xmetabolism |
| 650 | 0 | 4 |
_aFanconi Anemia Complementation Group D2 Protein _xmetabolism |
| 650 | 0 | 4 | _aFluorescent Antibody Technique |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aRNA Interference |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aTopoisomerase II Inhibitors _xpharmacology |
| 700 | 1 | _aLi, Li | |
| 700 | 1 | _aFournier, Loreen | |
| 700 | 1 | _aFerraiolo, Natalie | |
| 700 | 1 | _aDahm-Daphi, Jochen | |
| 700 | 1 | _aBorgmann, Kerstin | |
| 700 | 1 | _aWillers, Henning | |
| 773 | 0 |
_tCancer letters _gvol. 305 _gno. 1 _gp. 86-93 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.canlet.2011.02.030 _zAvailable from publisher's website |
| 999 |
_c20685354 _d20685354 |
||